Delivery technologies for cancer immunotherapy
2.1K
TL;DR: How recent developments in drug delivery could enable new cancer immunotherapies and improve on existing ones are discussed, and the current delivery obstacles are examined.
read more
Abstract: Immunotherapy has become a powerful clinical strategy for treating cancer. The number of immunotherapy drug approvals has been increasing, with numerous treatments in clinical and preclinical development. However, a key challenge in the broad implementation of immunotherapies for cancer remains the controlled modulation of the immune system, as these therapeutics have serious adverse effects including autoimmunity and nonspecific inflammation. Understanding how to increase the response rates to various classes of immunotherapy is key to improving efficacy and controlling these adverse effects. Advanced biomaterials and drug delivery systems, such as nanoparticles and the use of T cells to deliver therapies, could effectively harness immunotherapies and improve their potency while reducing toxic side effects. Here, we discuss these research advances, as well as the opportunities and challenges for integrating delivery technologies into cancer immunotherapy, and we critically analyse the outlook for these emerging areas.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Engineering precision nanoparticles for drug delivery
Michael J. Mitchell,Margaret M. Billingsley,Rebecca M Haley,Marissa E. Wechsler,Nicholas A. Peppas,Robert Langer +5 more
TL;DR: Advances in nanoparticle design that overcome heterogeneous barriers to delivery are discussed, arguing that intelligent nanoparticles design can improve efficacy in general delivery applications while enabling tailored designs for precision applications, thereby ultimately improving patient outcome overall.
A guide to cancer immunotherapy: from T cell basic science to clinical practice.
TL;DR: This guide to cancer immunotherapy provides a comprehensive historical and biological perspective regarding the advent and clinical implementation of cancer immunotherapeutics, with an emphasis on the fundamental importance of T lymphocyte regulation.
Top 10 Challenges in Cancer Immunotherapy
Priti S. Hegde,Daniel S. Chen +1 more
TL;DR: Ten key challenges facing cancer immunotherapy are defined, which range from lack of confidence in translating pre-clinical findings to identifying optimal combinations of immune-based therapies for any given patient.
1.7K
Immune-related adverse events of checkpoint inhibitors.
Manuel Ramos-Casals,Julie R. Brahmer,Margaret K. Callahan,Margaret K. Callahan,Alejandra Flores-Chávez,Niamh M. Keegan,Munther A. Khamashta,Olivier Lambotte,Xavier Mariette,Aleix Prat,Maria E. Suarez-Almazor +10 more
- 07 May 2020
TL;DR: This Primer by Ramos-Casals and colleagues summarizes the epidemiology, mechanisms, diagnosis and treatment of immune-related adverse events and should be prescribed carefully to reduce the potential of short-term and long-term complications.
993
Smart cancer nanomedicine
Roy van der Meel,Einar Sulheim,Einar Sulheim,Yang Shi,Fabian Kiessling,Willem J. M. Mulder,Willem J. M. Mulder,Twan Lammers,Twan Lammers,Twan Lammers +9 more
TL;DR: The use of nanomedicine in cancer requires the adoption of specific strategies to optimize its potential, and this perspective proposes four strategies including the identification of patients for clinical trials, investments in modular nanocarrier design, the integration in multimodal combination therapy regimes and the inclusion in immunotherapy studies.
References
Cancer Nanotechnology: The impact of passive and active targeting in the era of modern cancer biology
TL;DR: The fundamental concepts of enhanced permeability and retention effect (EPR) are revisited and the mechanisms proposed to enhance preferential "retention" in the tumor, whether using active targeting of nanoparticles, binding of drugs to their tumoral targets or the presence of tumor associated macrophages are explored.
2.6K
CAR T cell immunotherapy for human cancer
TL;DR: Opportunities and challenges for entering mainstream oncology that presently face the CAR T field are described, with a focus on the challenges that have emerged over the past several years.
2.4K
Adoptive cell transfer as personalized immunotherapy for human cancer.
TL;DR: The ability to genetically engineer lymphocytes to express conventional T cell receptors or chimeric antigen receptors has further extended the successful application of ACT for cancer treatment.
2.3K
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date.
Daniel Bobo,Kye J. Robinson,Jiaul Islam,Jiaul Islam,Kristofer J. Thurecht,Simon R. Corrie,Simon R. Corrie +6 more
TL;DR: An up to date snapshot of nanomedicines either currently approved by the US FDA, or in the FDA clinical trials process is provided, and there is a trend towards the development of more complex materials comprising micelles, protein-based NPs, and also the emergence of a variety of inorganic and metallic particles in clinical trials.
2.2K
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian,Mario Sznol,David F. McDermott,Harriet M. Kluger,Richard D. Carvajal,William H. Sharfman,Julie R. Brahmer,Donald P. Lawrence,Michael B. Atkins,John D. Powderly,Philip D. Leming,Evan J. Lipson,Igor Puzanov,David Smith,Janis M. Taube,Jon M. Wigginton,Georgia Kollia,Ashok Kumar Gupta,Drew M. Pardoll,Jeffrey A. Sosman,F. Stephen Hodi +20 more
TL;DR: Overall survival following nivolumab treatment in patients with advanced treatment-refractory melanoma compares favorably with that in literature studies of similar patient populations, and responses were durable and persisted after drug discontinuation.
Related Papers (5)
F. Stephen Hodi,Steven J. O'Day,David F. McDermott,R. W. Weber,Jeffrey A. Sosman,John B. A. G. Haanen,Rene Gonzalez,Caroline Robert,Dirk Schadendorf,Jessica C. Hassel,Wallace Akerley,Alfons J.M. van den Eertwegh,Jose Lutzky,Paul Lorigan,Julia Vaubel,Gerald P. Linette,David W. Hogg,Christian H. Ottensmeier,Céleste Lebbé,Christian Peschel,Ian Quirt,Joseph I. Clark,Jedd D. Wolchok,Jeffrey S. Weber,Jason Tian,Michael Yellin,Geoffrey M. Nichol,Axel Hoos,Walter J. Urba +28 more